Evidence Map
证据地图
| 患者层 | 外科 | 放疗 | 病理 | 影像 | 内科 | 综合管理 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 免疫 | 靶向 | ADC | 双抗 | 抗血管 | 化疗 | 其他 | 支持治疗 | 可及性/实施 | 照护路径 | ||||||
| 驱动基因阳性NSCLC | 局限/可切除 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 不可切除III期 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 转移性EGFR突变 | 0 | 0 | 0 | 0 | 1 | 7 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | |
| 转移性ALK阳性 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 转移性其他可操作驱动 | 0 | 0 | 2 | 0 | 0 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| 跨分期/范围未限定 | 0 | 1 | 0 | 0 | 0 | 21 | 2 | 3 | 0 | 2 | 0 | 0 | 0 | 0 | |
| 驱动基因阴性/未知NSCLC | 局限/可切除 | 20 | 4 | 5 | 2 | 11 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| 不可切除III期 | 2 | 4 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 转移性 | 1 | 5 | 2 | 1 | 10 | 1 | 2 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | |
| 跨分期/范围未限定 | 1 | 1 | 10 | 2 | 17 | 0 | 2 | 2 | 3 | 3 | 0 | 2 | 0 | 0 | |
| SCLC | 局限期 | 1 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 广泛期 | 0 | 2 | 0 | 1 | 6 | 0 | 0 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | |
| 转化型 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 分期未限定 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | |
| 其他肺癌相关人群 | 筛查/未定性肺结节人群 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 混合组织学/癌种未明确肺癌 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
局限/可切除NSCLC × 靶向
5项研究
- 42223087RET融合早期NSCLC进入辅助靶向随机证据阶段：塞普替尼显著延长EFS，但OS和三年用药负担仍待成熟Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.驱动基因阳性NSCLC› 局限/可切除早期IB期II-IIIA期潜在可切除RET融合辅助治疗
- 42418775ALK阳性可切除NSCLC辅助靶向再添III期证据：ELEVATE显示恩沙替尼显著延长DFS，OS未成熟且高级别不良事件更多Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.驱动基因阳性NSCLC› 局限/可切除IB期II期III期II-IIIB期可切除ALK融合辅助治疗
- 42458364切除后EGFR突变NSCLC辅助联合：OS与DFS合并结果有利，毒性同步增加Adjuvant chemotherapy with or without EGFR-TKIs for resected EGFR-mutated non-small cell lung cancer: a pooled analysis of four randomized controlled trials.驱动基因阳性NSCLC› 局限/可切除可切除EGFR突变辅助治疗
- 42458364辅助化疗加用EGFR-TKI使切除后EGFR突变NSCLC死亡风险相对降低44%Adjuvant chemotherapy with or without EGFR-TKIs for resected EGFR-mutated non-small cell lung cancer: a pooled analysis of four randomized controlled trials.驱动基因阳性NSCLC› 局限/可切除可切除EGFR突变辅助治疗
- 42563120IB期EGFR突变NSCLC辅助EGFR-TKI并非人人获益：真实世界研究提出降阶治疗可能De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study驱动基因阳性NSCLC› 局限/可切除早期IB期可切除EGFR突变辅助治疗手术
转移性EGFR突变NSCLC × 靶向
7项研究
- 41872782EGFR G719X+S768I共突变更支持二代TKI优先讨论：大型真实世界队列中阿法替尼ORR和PFS更高EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.驱动基因阳性NSCLC› EGFR突变转移性IV期EGFR罕见突变一线治疗含脑转移亚组含肝转移亚组
- 42090641转移性EGFR敏感突变NSCLC一线奥希替尼显示综合优势：目标试验模拟提示OS、毒性和资源利用优于二代TKI路径，但地区成本外推仍需谨慎Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer.驱动基因阳性NSCLC› EGFR突变转移性IV期EGFR突变一线治疗含脑转移亚组
- 42247790EGFR突变NSCLC脑膜转移强化治疗出现大样本信号：伏美替尼三联方案延长OS，但仍属于回顾性真实世界证据Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).驱动基因阳性NSCLC› EGFR突变转移性IV期脑膜转移EGFR突变后线治疗进展后
- 42379171EGFR突变CNS转移一线强化仍在寻找边界：伏美替尼160 mg II期显示颅内ORR 95.0%，但单臂研究不能替代随机比较High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.驱动基因阳性NSCLC› EGFR突变晚期（范围未限定）转移性IV期脑转移EGFR突变一线治疗
- 42373731一线奥希替尼后耐药机制高度分散：CAPTRA-LUNG队列提示进展后复检仍是后线治疗选择的前提Acquired resistance to first-line osimertinib is heterogeneous in EGFR-mutant advanced non-small cell lung cancer.驱动基因阳性NSCLC› EGFR突变晚期（范围未限定）转移性IV期EGFR突变进展后后线治疗进展
- 42442920EGFR突变NSCLC联合策略：Ib期跨队列差异不能证明治疗获益BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.驱动基因阳性NSCLC› EGFR突变转移性IV期EGFR突变
- 42530663一线EGFR-TKI进展后：过半T790M阴性晚期NSCLC仍在用靶向单药Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).驱动基因阳性NSCLC› EGFR突变转移性IV期EGFR突变后线治疗进展后
转移性EGFR突变NSCLC × 化疗
1项研究
- 41886013EGFR突变软脑膜转移后线仍缺标准答案：达可替尼联合脑室内培美曲塞小队列显示可行，但疗效边界有限Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third-generation EGFR-TKIs in EGFR-mutant NSCLC: an ambispective cohort study.驱动基因阳性NSCLC› EGFR突变转移性脑膜转移EGFR突变后线治疗进展后进展耐药
转移性ALK阳性NSCLC × 靶向
2项研究
- 41728837洛拉替尼提高ALK阳性NSCLC脑转移的颅内ORR：8项随机试验Meta分析显示可测量脑转移患者相对对照的颅内ORR RR为3.57，完全缓解率RR为4.04Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.驱动基因阳性NSCLC› ALK阳性转移性IV期脑转移ALK融合一线治疗
- 41949116经二代ALK抑制剂后洛拉替尼仍有确认性活性：phase IV研究显示ORR 42%，中枢转移者颅内ORR 47%Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.驱动基因阳性NSCLC› ALK阳性转移性IV期ALK融合后线治疗进展后进展含脑转移亚组
转移性其他可操作驱动NSCLC × 病理
2项研究
- 42338283进展后液体活检CGP可补足组织复检盲区：TSO500与Guardant360比较显示关键驱动和融合检出一致性较高Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.驱动基因阳性NSCLC› 其他可操作驱动转移性IV期驱动阳性后线治疗进展后进展
- 42528143影像稳定≠分子静止：ctDNA在KRAS G12C突变NSCLC中提前10周捕获多克隆耐药ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.驱动基因阳性NSCLC› 其他可操作驱动转移性IV期KRAS G12C进展后
转移性其他可操作驱动NSCLC × 靶向
5项研究
- 41879829KRAS G12D有了可讨论的药物信号：setidegrasib phase 1研究在经治晚期NSCLC中显示36%缓解率，但仍属早期验证Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.驱动基因阳性NSCLC› 其他可操作驱动转移性KRAS G12D后线治疗进展
- 41886723RET融合NSCLC的普拉替尼随访更成熟：ARROW最终分析确认高缓解率和长期OS，也补充严重毒性边界Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.驱动基因阳性NSCLC› 其他可操作驱动转移性RET融合一线治疗后线治疗
- 41872688驱动阳性NSCLC不能用高PD-L1简单转向免疫：回顾性队列显示TPS ≥50%反而伴随靶向治疗结局较差Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.驱动基因阳性NSCLC› 其他可操作驱动转移性IV期驱动阳性一线治疗
- 41985129HER2突变NSCLC一线靶向治疗出现强信号：zongertinib单臂phase 1a-1b研究ORR达76%，但仍需随机证据确定处方位置First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.驱动基因阳性NSCLC› 其他可操作驱动晚期（范围未限定）转移性IV期HER2突变一线治疗含脑转移亚组
- 42546514BRAF融合：罕见驱动事件，也是EGFR-TKI耐药的新路径BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer驱动基因阳性NSCLC› 其他可操作驱动转移性IV期驱动阳性后线治疗进展后
跨分期/范围未限定NSCLC × 放疗
1项研究
- 42363769第三代EGFR TKI同步胸部放疗需前置肺炎风险评估：209例队列显示2级以上放射性肺炎达43.54%，剂量体积参数影响明显Reassessing the Incidence and Risk Factors of Radiation Pneumonitis in Treatment-Naive EGFR-Mutant NSCLC With Concurrent Third-Generation EGFR-TKI and Thoracic Radiotherapy.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）不可切除EGFR突变一线治疗
跨分期/范围未限定NSCLC × 靶向
21项研究
- 41711491第三代EGFR-TKI普及使常见EGFR突变晚期NSCLC真实世界中位OS达29.3个月FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR敏感突变一线治疗
- 41747608化疗联合EGFR-TKI与PACC突变NSCLC更长OS相关：141例多中心回顾性队列显示联合治疗中位OS为30.5个月，高于单纯化疗的24.1个月和EGFR-TKI的28.9个月Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR PACC突变一线治疗含脑转移亚组
- 41790042ELIOS揭示一线奥希替尼进展后的耐药图谱高度异质：前瞻性分子分型支持组织与血浆复检互补，但不能直接给出后线用药答案ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变一线治疗进展后进展耐药
- 41801573奥希替尼心脏安全性需要主动监测：Meta分析显示心衰和LVEF下降风险高于其他EGFR抑制剂Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变一线治疗后线治疗
- 41945500RET抑制剂再治疗需要区分停药原因：RET-MAP提示毒性换药可行，进展后同类再挑战获益有限Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）RET融合后线治疗进展后进展
- 41981516一线奥希替尼总体心血管复合风险未升高：TriNetX真实世界分析提示年轻患者心衰信号仍需随访Real-world cardiovascular risk comparison of first-line osimertinib and earlier generation EGFR-TKIs in EGFR-mutated NSCLC: a TriNetX USA network analysis.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变一线治疗
- 41974115洛拉替尼神经精神AE需要主动询问：FAERS药物警戒分析显示认知、情绪、言语和精神症状均有报告信号Neuropsychiatric adverse events associated with lorlatinib in ALK-positive NSCLC.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）ALK融合一线治疗后线治疗
- 42013573taletrectinib在ROS1阳性NSCLC中显示长期疾病控制：TRUST-I长随访一线mPFS接近50个月，但药物排序仍需比较证据Long-Term Efficacy and Safety of Taletrectinib in Patients With Advanced ROS1-Positive Non-Small Cell Lung Cancer.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）ROS1阳性一线治疗后线治疗含脑转移亚组
- 42071190非常见EGFR exon 19缺失不宜再笼统处理：双中心真实世界研究提示亚型间PFS差异，但阿美替尼优先地位仍需更强比较证据Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变一线治疗复发
- 42155306repotrectinib联合奥希替尼Ib期结果：EGFR突变耐药NSCLC中ORR 22.2%，3-4级TRAE 45.2%Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变进展后后线治疗进展耐药含脑转移亚组
- 42191070EGFR PACC复合突变更接近二代TKI敏感构型：cfDNA、体外模型和真实世界资料提示报告突变构型有临床价值Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR PACC突变EGFR复合突变靶向治疗选择
- 42174600MET exon14跳跃突变治疗解释需要带上共改变和耐药路径：585例分子队列细化基线与进展后复测重点Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）MET 14号外显子跳跃突变靶向治疗选择进展后耐药
- 42212913EGFR exon20ins一线治疗出现口服靶向III期证据：舒沃替尼较含铂化疗延长PFS，但与埃万妥单抗联合化疗的排序仍未解决First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR 20号外显子插入一线治疗
- 42217582洛拉替尼一线ALK阳性NSCLC控制可延续至七年：CROWN长期更新巩固PFS和颅内优势，但OS仍未成熟Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）ALK融合一线治疗含脑转移亚组
- 42218657罕见EGFR突变一线TKI选择应细化到具体亚型：真实世界比较显示阿法替尼与奥希替尼总体结局相近，但亚型方向不同Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR罕见突变一线治疗
- 42284541BRAF V600E NSCLC可用早期ctDNA变化做监测假设：LiBRA显示4周清除与PFS和OS相关Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）BRAF V600E一线治疗
- 42341249ALK阳性NSCLC真实获益受药物可及性限制：巴西队列显示公私系统一线ALK抑制剂使用率和3年OS差距明显Treatment of ALK+ Non-Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918).驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）ALK融合一线治疗后线治疗
- 42374111罕见ALK融合不应退回化疗优先：29中心真实世界队列显示一线ALK TKI疗效接近EML4-ALK，化疗PFS明显较短Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）ALK融合一线治疗
- 42413526KRAS G12C一线去化疗方案出现早期强信号：ifebemtinib联合格索雷塞单臂队列ORR 82%，随机III期才是临床位置的关键Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.驱动基因阳性NSCLC› 跨分期/范围未限定III-IV期（跨范围）KRAS G12C一线治疗
- 42409117驱动阳性NSCLC的MTAP缺失不只是靶点线索：JTO大队列显示EGFR突变一线靶向人群预后更差，IHC与NGS一致性较高Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights from a Large-Scale Real-World Chinese Cohort.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）驱动阳性一线治疗
- 42444983ROS1阳性NSCLC脑转移的靶向衔接：颅内控制与进展后用药需合并判断Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）ROS1阳性进展后靶向治疗选择含脑转移亚组
跨分期/范围未限定NSCLC × ADC
2项研究
- 41747890T-DXd在HER2突变NSCLC脑转移中的颅内ORR达74.1%：68中心真实世界研究显示全队列ORR为54.8%，ILD或肺炎发生率为14%，包括4例死亡Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）HER2突变后线治疗含脑转移亚组
- 41780641奥希替尼进展后可保留EGFR抑制骨架联合TROP2 ADC：ORCHARD单臂模块显示Dato-DXd联合奥希替尼有后线活性，但毒性与剂量选择仍需随机验证Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变一线治疗进展后进展耐药
跨分期/范围未限定NSCLC × 双抗
3项研究
- 41945065EGFR exon20ins经含铂后NSCLC：埃万妥单抗外部对照比较显示PFS、ORR和OS均优于台湾真实世界治疗Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR 20号外显子插入后线治疗进展后进展
- 42192224中国大陆EGFR exon20ins人群补足PAPILLON本地证据：埃万妥单抗联合卡铂/培美曲塞延长PFS，但仍是地区亚组分析Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.驱动基因阳性NSCLC› 跨分期/范围未限定III-IV期（跨范围）EGFR 20号外显子插入一线治疗
- 42307937EGFR-TKI后进展有了OS阳性联合方案：HARMONi-A最终分析显示依沃西单抗联合化疗优于化疗，毒性负担同步上升Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.驱动基因阳性NSCLC› 跨分期/范围未限定III-IV期（跨范围）EGFR突变后线治疗进展后
跨分期/范围未限定NSCLC × 化疗
2项研究
- 41818162EGFR突变合并抑癌基因共突变不一定只靠TKI：ACROSS2显示阿美替尼联合卡铂-培美曲塞延长PFS，但OS仍不成熟Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.驱动基因阳性NSCLC› 跨分期/范围未限定晚期（范围未限定）EGFR突变一线治疗
- 42296979一线EGFR治疗继续走向联合强化：AENEAS2延长PFS，但血液毒性和OS未成熟限制了默认化Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.驱动基因阳性NSCLC› 跨分期/范围未限定III-IV期（跨范围）EGFR突变EGFR敏感突变一线治疗
局限/可切除NSCLC × 外科
20项研究
- 41679123重度衰弱与I期NSCLC术后并发症及死亡风险升高相关The impact of frailty on postoperative outcomes of veterans with stage I non-small cell lung cancer.驱动基因阴性/未知NSCLC› 局限/可切除I期可切除手术
- 41681095早期NSCLC肺叶切除：机器人术式与更高生活质量和费用相关Comparison of Robotic-Assisted and Uniportal Video-Assisted Thoracoscopic Lobectomy for Early-Stage Non-Small Cell Lung Cancer: A Retrospective Cohort Study.驱动基因阴性/未知NSCLC› 局限/可切除早期可切除手术
- 41702848六项常规指标评分可中等区分合并特发性肺纤维化肺癌患者术后肺部并发症的高低风险人群Predicting Postoperative Complications in Patients With Lung Cancer and Idiopathic Pulmonary Fibrosis.驱动基因阴性/未知NSCLC› 局限/可切除可切除
- 41746575免疫治疗后转化手术的3年RFS高于真正挽救手术：14中心回顾性队列显示两组3年RFS分别为92.8%和36.3%，围手术期并发症率为25.0%Efficacy and Safety of Salvage Surgery After Immunotherapy in Non-small Cell Lung Cancer: A Multi-institutional Retrospective Study.驱动基因阴性/未知NSCLC› 局限/可切除局部晚期潜在可切除
- 41794095bulky N2期NSCLC新辅助化免后不应过早排除手术：回顾性队列显示手术组EFS和OS更佳，但选择偏倚决定其只能作为MDT信号Neoadjuvant Chemoimmunotherapy Followed by Surgery or Radiotherapy for Stage IIIA-B Non-Small Cell Lung Cancer With Bulky N2 Disease.驱动基因阴性/未知NSCLC› 局限/可切除局部晚期III期可切除新辅助治疗新辅助治疗后
- 41770564SBRT时代未能自动消除早期NSCLC根治治疗差异：SEER-Medicare研究显示Black患者接受根治性治疗概率持续较低Early-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries.驱动基因阴性/未知NSCLC› 局限/可切除早期I期II期
- 41864749VATS肺叶切除的长期肿瘤学证据更硬了：随机试验个体患者数据荟萃显示早期NSCLC较开胸有OS优势，DFS未受损Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.驱动基因阴性/未知NSCLC› 局限/可切除早期可切除可手术
- 4192286190岁以上IA期NSCLC不能只按年龄排除手术：NCDB匹配分析显示手术OS优于放疗，但选择偏倚很重Surgery Versus Radiation for Stage 1A NSCLC in Nonagenarians: 20 Years of Data, Decisions, and Outcomes.驱动基因阴性/未知NSCLC› 局限/可切除早期IA期
- 41980306cN3 NSCLC术前免疫化疗后手术需限定人群：双中心回顾性队列提示获益主要集中在pCR或ypN0患者Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.驱动基因阴性/未知NSCLC› 局限/可切除局部晚期IIIB期IIIC期潜在可切除新辅助治疗
- 41984418磨玻璃为主早期NSCLC段切除可关注症状恢复：前瞻性症状数据提示不完全解剖性段切除术后咳嗽负担较低Thoracoscopic Incomplete Anatomical Segmentectomy for Ground-Glass-Dominant Lung Cancer: Associations with Lower Postoperative Cough Burden and Faster Symptom Recovery.驱动基因阴性/未知NSCLC› 局限/可切除早期IA1期IA2期可切除手术
- 41981405I期NSCLC手术与SBRT长期结局仍受选择偏倚影响：两中心队列显示总体相近，但SBRT后远处转移更多Comparison of prognosis between patients undergoing surgical resection and stereotactic ablative radiotherapy for early-stage lung cancer.驱动基因阴性/未知NSCLC› 局限/可切除早期I期可切除医学不可手术局部治疗
- 42034855IPF合并病理I期NSCLC术后局部复发风险更高：回顾性手术队列提示术后监测和抗纤维化研究需要前置Idiopathic pulmonary fibrosis predicts local recurrence following surgery in patients with non-small cell lung cancer.驱动基因阴性/未知NSCLC› 局限/可切除早期I期合并ILD
- 42067843术前嗜酸细胞升高可提示早期NSCLC术后资源需求：双队列回顾性研究关联90天医疗利用和1年生存，但不应直接改变手术适应证Blood eosinophil counts and postoperative outcomes in early-stage lung cancer: a retrospective cohort study.驱动基因阴性/未知NSCLC› 局限/可切除早期I期II期潜在可切除
- 42119729IA期外周NSCLC肺段切除术不能只看生存趋势：JCOG0802/WJOG4607L事后分析显示局部区域复发升高，术后侵袭性病理特征应触发更细随访和补充治疗讨论Segmentectomy versus lobectomy in non-small-cell lung cancer with pathologically invasive features: a post-hoc supplementary analysis of a multicenter, Phase 3 trial JCOG0802/WJOG4607L.驱动基因阴性/未知NSCLC› 局限/可切除早期IA期可切除手术
- 42114598合并ILD的早期肺癌仍可评估局部根治治疗：转诊中心队列显示手术和SABR结局相近，但肺纤维化进展决定风险层级Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease.驱动基因阴性/未知NSCLC› 局限/可切除早期I期II期手术合并ILD
- 42234674新辅助治疗后淋巴结阳性NSCLC不宜轻易缩小切除范围：NCDB队列显示亚肺叶切除与III期患者长期生存较差相关Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer.驱动基因阴性/未知NSCLC› 局限/可切除II期III期可切除新辅助治疗后手术
- 42223938肺癌切除术遵循“3+1”淋巴结取样规则未增加并发症：大型胸外科数据库支持规范分期的实施安全性Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection.驱动基因阴性/未知NSCLC› 局限/可切除早期可切除手术
- 42331211IA3期NSCLC不宜把楔形切除等同于解剖性亚肺叶切除：单中心队列显示复发和DFS方向不同Outcomes of Lobectomy Versus Sublobar Resection for Clinical Stage IA3 Non-Small Cell Lung Cancer.驱动基因阴性/未知NSCLC› 局限/可切除早期IA3期可切除手术
- 42340681CPET不宜作为NSCLC肺切除风险的单一闸门：353例队列显示VO2peak和AT区分术后并发症能力很弱Preoperative cardiopulmonary exercise testing and 30-day postoperative complications after lung resection for non-small cell lung cancer: a retrospective cohort study.驱动基因阴性/未知NSCLC› 局限/可切除可切除手术
- 42556446术前化疗联合度伐利尤单抗提高N2淋巴结清除率：可切除III期NSCLC治疗路径出现新选择CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer(AFT-46)驱动基因阴性/未知NSCLC› 局限/可切除III期可切除新辅助化疗-免疫治疗新辅助治疗后手术
局限/可切除NSCLC × 放疗
4项研究
- 41833909医学不可手术外周早期NSCLC可考虑更简分割：随机II期长期分析显示单次SBRT与三次方案结局相近Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.驱动基因阴性/未知NSCLC› 局限/可切除早期I期II期医学不可手术
- 42264097潜在可切除III期NSCLC加入低剂量SBRT仍属早期探索：帕博利珠单抗化疗前置方案出现高病理反应和致死性出血Low-Dose Stereotactic Body Radiation Therapy-Based Radiation Therapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase 1b Study.驱动基因阴性/未知NSCLC› 局限/可切除局部晚期III期潜在可切除新辅助治疗
- 42431270早期NSCLC肺SBRT后局部控制：报告范围与进展标准需同时明确Inconsistent definitions of local control for stereotactic body radiation therapy for early-stage lung cancer - A systematic review.驱动基因阴性/未知NSCLC› 局限/可切除早期不可切除
- 42486309早期NSCLC的SBRT计划可加入免疫器官剂量约束First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study.驱动基因阴性/未知NSCLC› 局限/可切除早期不可切除
局限/可切除NSCLC × 病理
5项研究
- 41723072局限期NSCLC术后人群中，KEAP1突变与更差预后的关联获独立队列验证Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.驱动基因阴性/未知NSCLC› 局限/可切除可切除
- 41922144术后复发NSCLC的多基因检测瓶颈不只是标本不足：WJOG15421L亚组显示检测率仍偏低Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.驱动基因阴性/未知NSCLC› 局限/可切除早期进展后复发
- 42002075术后ctDNA阴性仍需再分层：LAMPAD模型在切除NSCLC中区分2年DFS约98%与72%人群，但尚不能指导减免辅助治疗LAMPAD:An Integrated ctDNA-Based Model for Predicting Potential Cure in Resected NSCLC Patients.驱动基因阴性/未知NSCLC› 局限/可切除I期II期III期可切除辅助治疗
- 42229633新辅助治疗后MPR评估可由数字病理提高一致性：IASLC项目显示机器学习与病理医师高度相关，但尚不能替代人工复核Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.驱动基因阴性/未知NSCLC› 局限/可切除可切除新辅助治疗后病理评估
- 42456087术后电子病历提醒将早期非鳞NSCLC全面分子检测完成率从36.9%提高至81.1%EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.驱动基因阴性/未知NSCLC› 局限/可切除早期手术
局限/可切除NSCLC × 影像
2项研究
- 42030509肺癌幸存者转入基层随访后胸部CT达标率下降：VHA队列提示随访责任交接会影响指南一致性Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for Lung Cancer Survivors in a Nationwide Health Care System.驱动基因阴性/未知NSCLC› 局限/可切除I期II期III期
- 42283747侵袭性NSCLC筛查窗口可能小于常规想象：治愈阈值分析把小结节处理变成LDCT获益的关键变量How Wide is the Screening Window for Aggressive Non-Small Cell Lung Cancers? The Cure Threshold Metric and its Implications for Lung Cancer Screening Guidelines.驱动基因阴性/未知NSCLC› 局限/可切除早期
局限/可切除NSCLC × 免疫
11项研究
- 41915945新辅助免疫后辅助免疫不宜自动补满：II-IIIB期NSCLC回顾性匹配研究未见明确生存增益Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer.驱动基因阴性/未知NSCLC› 局限/可切除II-IIIB期可切除辅助治疗新辅助治疗后
- 42003237非鳞NSCLC新辅助阿替利珠单抗联合化疗显示病理缓解：单臂II期MPR为45%，但高级别毒性限制了直接推广Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.驱动基因阴性/未知NSCLC› 局限/可切除IIA-IIIB期可切除新辅助治疗
- 42114951可切除鳞状NSCLC围手术期斯鲁利单抗方案显示病理缓解信号：单臂II期MPR为76.67%，但长期结局和相对优势仍待随机验证Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis.驱动基因阴性/未知NSCLC› 局限/可切除II-IIIA期可切除驱动阴性新辅助治疗辅助治疗围手术期
- 42145107新辅助免疫化疗与术后AHRF：双中心队列显示nICT组AHRF发生率高于新辅助化疗组Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.驱动基因阴性/未知NSCLC› 局限/可切除II-IIIB期可切除新辅助治疗围手术期
- 42154108辅助化免与淋巴结清扫范围：NCDB病理II-III期NSCLC分析显示高LND组仍有OS信号Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.驱动基因阴性/未知NSCLC› 局限/可切除病理II-III期可切除辅助治疗
- 42224490术后单独追加纳武利尤单抗未改善DFS：阴性III期结果提醒围手术期免疫获益不能跨时序外推Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.驱动基因阴性/未知NSCLC› 局限/可切除可切除EGFR野生型ALK野生型辅助治疗
- 42217119新辅助免疫化疗后应前置评估术后房颤风险：匹配队列显示房颤发生率阶梯式升高并延长住院Neoadjuvant immunotherapy and the stepwise risk of postoperative atrial fibrillation: a propensity score-matched analysis isolating surgical and biological triggers.驱动基因阴性/未知NSCLC› 局限/可切除II期III期可切除新辅助化疗-免疫治疗手术
- 42264017II期NSCLC新辅助化免选择需要风险分层：IPD重建分析显示OS结论受TNM参照人群影响STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY.驱动基因阴性/未知NSCLC› 局限/可切除II期可切除新辅助治疗
- 42252705新辅助信迪利单抗化疗三周期未胜过两周期：neoSCORE最终分析把疗程数问题拉回个体化决策Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.驱动基因阴性/未知NSCLC› 局限/可切除IB期IIIA期II期可切除新辅助治疗
- 42364306新辅助化免后PD-L1 TPS预测病理缓解的短板不是阅片差异造成：30名病理医师读片显示TPS与残余活肿瘤相关性仍弱Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability.驱动基因阴性/未知NSCLC› 局限/可切除II-IIIA期可切除新辅助治疗
- 42455561围手术期特瑞普利单抗联合化疗较化疗让更多可切除III期NSCLC患者完成手术Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.驱动基因阴性/未知NSCLC› 局限/可切除III期可切除围手术期
局限/可切除NSCLC × 化疗
1项研究
- 42379045辅助化疗能否完成可在术前提前讨论：2100例II-IIIA期NSCLC队列显示Eurolung morbidity score预测治疗未完成Preoperative eurolung score predicts non-completion of adjuvant chemotherapy in resected stages II-III non-small cell lung cancer: Implications for perioperative systemic therapy delivery.驱动基因阴性/未知NSCLC› 局限/可切除II-IIIA期可切除辅助治疗围手术期
不可切除III期NSCLC × 外科
2项研究
- 41880079初始不可切除III期NSCLC可保留转化手术窗口：前瞻性proof-of-concept研究显示筛选后R0切除率93.3%Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除新辅助治疗后
- 42303632不可切除III期NSCLC能否被诱导后重新分流：TRAILBLAZER更新提供信号，仍受响应选择影响Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除EGFR野生型新辅助治疗巩固治疗
不可切除III期NSCLC × 放疗
4项研究
- 41760405PACIFIC路径的PFS优于诱导免疫化疗后放疗：183例回顾性队列显示同步放化疗后免疫巩固的中位PFS为26.8个月，诱导免疫化疗后放疗为16.4个月Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort study.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除巩固治疗
- 42201929老年或虚弱III期NSCLC的胸部放疗强度可以前瞻性下调：随机II期非比较队列显示减量方案可行，但不能证明非劣效Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除序贯化疗-免疫治疗
- 42199487诱导免疫化疗后仍不可手术NSCLC可讨论单纯根治放疗：回顾性加权比较显示PFS相近且血液毒性更低Definitive radiotherapy provides comparable survival with lower toxicity compared with concurrent chemoradiotherapy after long-course induction chemoimmunotherapy in unresectable non-small-cell lung cancer.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除驱动阴性诱导治疗后
- 42462186放疗联合度伐利尤单抗2年PFS超过预设历史基准，支持作为同步放化疗不适用患者的根治性备选Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除
不可切除III期NSCLC × 免疫
5项研究
- 41911546bulky不可切除III期NSCLC可探索诱导免疫化疗后接cCRT：SUCCEED-01显示可行性，但不能替代标准路径Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01).驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除新辅助治疗巩固治疗
- 42141789不可切除III期NSCLC免疫治疗时序：诱导加巩固与单纯巩固ICI在匹配后PFS和OS相近Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除巩固治疗
- 42336205III期NSCLC巩固免疫期间MRD监测更接近复发预警：前瞻队列显示度伐利尤单抗中后期ctDNA阳性与PFS显著变差相关ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除巩固治疗
- 42398520PACIFIC巩固免疫前的合并用药需要被看见：事后分析显示基线PPI和抗生素暴露与度伐利尤单抗获益减弱相关Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.驱动基因阴性/未知NSCLC› 不可切除III期局部晚期III期不可切除巩固治疗
- 42562209不可切除III期NSCLC：tiragolumab联合阿替利珠单抗巩固未优于度伐利尤单抗SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation驱动基因阴性/未知NSCLC› 不可切除III期III期不可切除巩固治疗同步放化疗
转移性NSCLC × 放疗
5项研究
- 41677281减量SRS与较少放射损伤相关，NSCLC脑转移局控率相近Stereotactic Radiosurgery Dose Reduction for Patients With Brain Metastases From Non-Small Cell Lung Primary on Immunotherapy or Targeted Therapy.驱动基因阴性/未知NSCLC› 转移性转移性IV期局部治疗
- 41720018同步寡转移NSCLC根治治疗后，近三分之二的进展表现为寡进展Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.驱动基因阴性/未知NSCLC› 转移性转移性IV期
- 41961169转移性NSCLC胸部放疗有生存信号也有肺毒性代价：回顾性队列支持按分子亚型和靶区风险个体化The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy.驱动基因阴性/未知NSCLC› 转移性转移性IV期一线治疗
- 42121314老年晚期NSCLC一线化免后加胸部放疗需谨慎：回顾性队列未见显著生存获益，肺炎和治疗中断成为主要边界Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non-Small Cell Lung Cancer.驱动基因阴性/未知NSCLC› 转移性转移性IV期驱动阴性一线治疗
- 42157246骨寡转移NSCLC的SBRT结果：欧洲15中心队列报告2年局部复发自由率87.2%Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.驱动基因阴性/未知NSCLC› 转移性转移性IV期骨转移后线治疗
转移性NSCLC × 病理
2项研究
- 41951723疑似转移性NSCLC组织不可及时可先做cfDNA NGS：前瞻性项目检出EGFR、BRAF V600E和KRAS G12C靶点Prospective clinical evaluation of cell-free DNA next generation sequencing in patients with suspected metastatic lung cancer.驱动基因阴性/未知NSCLC› 转移性转移性IV期
- 42489696ctDNA早期分层信号明确，单独指导换药仍证据不足Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.驱动基因阴性/未知NSCLC› 转移性转移性IV期一线治疗后线治疗
转移性NSCLC × 影像
1项研究
- 41872110非驱动依赖转移性NSCLC脑转移监测可更个体化：CRISP注册研究建立并验证18个月脑转移风险分类器Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).驱动基因阴性/未知NSCLC› 转移性转移性驱动阴性
转移性NSCLC × 免疫
10项研究
- 41690366DICIPLE试验提示双免疫治疗6个月停药可减少重度不良事件Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.驱动基因阴性/未知NSCLC› 转移性转移性IV期驱动阴性一线治疗诱导治疗后
- 41871218ECOG 3-4经治NSCLC仍可保留免疫治疗讨论：小型匹配研究显示纳武利尤单抗较BSC有生存信号，但选择偏倚很重Nivolumab versus Best Supportive Care after Failure of Chemotherapy in Non-Small Cell Lung Cancer Patients with ECOG 3 or 4: A Propensity-Matched Analysis.驱动基因阴性/未知NSCLC› 转移性转移性IV期后线治疗低PS
- 41896648后线鳞状NSCLC出现少见随机OS信号：PRESERVE-003第一阶段显示gotistobart优于多西他赛，但仍需等待第二阶段复现Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.驱动基因阴性/未知NSCLC› 转移性转移性IV期驱动阴性后线治疗进展后
- 42149140从不吸烟AGA阴性NSCLC的PD-(L)1治疗结局：PD-L1极高、TMB高和免疫浸润与获益相关Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.驱动基因阴性/未知NSCLC› 转移性转移性IV期驱动阴性一线治疗
- 42159393转移性NSCLC一线治疗可及性：美国真实世界数据观察到免疫治疗使用率和启动时间差异Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer.驱动基因阴性/未知NSCLC› 转移性转移性IV期一线治疗
- 42331381PD-1失败后免疫再挑战仍可探索：RECLAIM显示放疗联合CTLA-4/PD-1双免有缓解信号，但单臂II期不能改写后线标准Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.驱动基因阴性/未知NSCLC› 转移性转移性IV期后线治疗进展后
- 42360104双免一线治疗的早期风险需要前置识别：CheckMate 227/9LA事后分析显示纳武利尤单抗+伊匹木单抗早期进展率高于化疗，加化疗后早期劣势减弱Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.驱动基因阴性/未知NSCLC› 转移性转移性IV期驱动阴性一线治疗
- 42378718TMB低NSCLC免疫获益仍可再分层：MSK-CHORD显示APOBEC阳性与ICI治疗OS改善相关，PD-L1阴性人群信号更突出APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.驱动基因阴性/未知NSCLC› 转移性转移性IV期TMB低一线治疗后线治疗
- 42440365PD-L1高表达晚期NSCLC：ctDNA肿瘤分数暂不单独决定是否加化疗Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.驱动基因阴性/未知NSCLC› 转移性转移性IV期
- 42485593黎巴嫩危机中的免疫治疗减量，为供应中断预案提供现实依据Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non-Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon.驱动基因阴性/未知NSCLC› 转移性转移性IV期一线治疗后线治疗
转移性NSCLC × ADC
2项研究
- 41871716Dato-DXd联合帕博利珠单抗前移仍需随机试验回答：TROPION-Lung02显示一线活性，三联毒性更高且未见清晰增益Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.驱动基因阴性/未知NSCLC› 转移性转移性驱动阴性一线治疗
- 41961582一线ADC联合免疫化疗进入NSCLC探索阶段：EVOKE-02显示戈沙妥珠单抗联合帕博利珠单抗和卡铂有活性，但重度AE负担较高First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.驱动基因阴性/未知NSCLC› 转移性转移性IV期驱动阴性一线治疗
转移性NSCLC × 支持治疗
2项研究
- 42126766晚期NSCLC减药机会需要结构化识别：817例观察研究显示算法标记率高，但真正可减药仍依赖临床证据和患者意愿Deprescribing opportunities for patients with advanced non-small cell lung cancer: an observational study of potentially inappropriate medications and stakeholders' perspectives.驱动基因阴性/未知NSCLC› 转移性转移性IV期
- 42558967Dato-DXd治疗NSCLC毒性管理进入规范化阶段：国际专家共识提出多学科管理路径Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee驱动基因阴性/未知NSCLC› 转移性转移性IV期后线治疗
跨分期/范围未限定NSCLC × 病理
10项研究
- 41690367TTF-1阴性与肺腺癌免疫治疗后较短PFS、OS相关TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.驱动基因阴性/未知NSCLC› 跨分期/范围未限定转移性III期IV期
- 41786210肺鳞癌全面NGS并非低收益操作：真实世界队列显示诊断重分类和可靶向改变可直接影响治疗路径Clinical Utility of Next-Generation Sequencing in Tumors Diagnosed as Lung Squamous Cell Carcinoma: Real-World Data of Diagnostic and Therapeutic Implications.驱动基因阴性/未知NSCLC› 跨分期/范围未限定
- 41797649NSCLC反射性生物标志物检测缩短诊疗等待：系统综述显示周转和一线精准治疗使用改善，但收益依赖流程设计Systematic review of reflex biomarker testing and its influence on diagnostic and treatment timelines in cancer pathways.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗
- 41945413EBUS-TBNA仍是分期和分子检测入口：双中心回顾性研究显示高诊断准确度和可用组织率Endobronchial ultrasound-guided transbronchial fine-needle aspiration of mediastinal lymph nodes: a clinical appraisal of diagnostic accuracy and molecular utility.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）
- 41981524越南NSCLC真实世界队列显示检测和治疗可及性改善伴随生存延长：低中收入环境下分子检测扩展仍是核心抓手Real-world trends in diagnosis, treatment, and survival of non-small cell lung cancer in Vietnam.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）早期转移性III期IV期一线治疗
- 42018972晚期NSCLC分子检测不能只看下单率：美国社区队列显示治疗前有效检测率仅72%，首程精准治疗仍受流程延迟限制Evaluating Effective Biomarker Testing for Advanced Non-Small Cell Lung Cancer in US Community Oncology Practices.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）一线治疗
- 42001597进展后序贯血浆CGP可改变部分NSCLC管理：真实世界队列显示13%患者获得独特管理信息，但常规高频复检仍缺少前瞻性策略证据Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）进展后后线治疗进展耐药
- 42036879ctDNA可作为EGFR检测的现实补充而非普遍替代：32例横断面研究显示晚期NSCLC一致性较好，但阴性结果仍需组织确认Circulating tumor DNA: An alternative to tissue biopsy for detecting epidermal growth factor receptor mutation in non-small cell lung cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定早期转移性IV期一线治疗
- 42101621NSCLC分子检测质量控制应前移到NCP评估：观察者研究显示肿瘤细胞比例误判会增加后续检测决策错误The critical role of accurate neoplastic cell percentage (NCP) assessment: investigating targeted training strategies for pulmonary biopsy and cytology specimens.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）
- 42475517EBUS-TBNA组织NGS较血液NGS检出更多NSCLC临床相关突变，血液阴性不能替代组织检测Clinical Utility of Next Generation Sequencing in Concurrent EBUS-TBNA and Liquid Biopsies in NSCLC.驱动基因阴性/未知NSCLC› 跨分期/范围未限定
跨分期/范围未限定NSCLC × 影像
2项研究
- 42116286PET/CT支持NSCLC初始远处转移分期：诊断准确性Meta分析显示特异性高，增强CT整合可稳定敏感性Diagnostic accuracy of 18F-FDG PET/CT scan in distant metastasis staging of non-small cell lung cancer: A meta-analysis.驱动基因阴性/未知NSCLC› 跨分期/范围未限定
- 42249940结核高发地区III期NSCLC需警惕PET-CT纵隔过分期：EBUS对照显示SUV阈值可能需要本地校准Mediastinal over-staging with PET-CT in tuberculosis-endemic locally advanced NSCLC: SUV threshold recalibration improves PET/EBUS concordance.驱动基因阴性/未知NSCLC› 跨分期/范围未限定局部晚期III期治疗前分期
跨分期/范围未限定NSCLC × 免疫
17项研究
- 41699769铂类不适用NSCLC中，阿替利珠单抗延长生存的优势经历史校正后依然成立Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）一线治疗
- 41702355晚期NSCLC双免疫治疗者中，基线肠道菌群多样性高与更长PFS、OS相关Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）
- 41176784HIV阳性晚期NSCLC不应被机械排除在化免治疗外：小样本比较研究显示替雷利珠单抗联合化疗短期疗效接近HIV阴性对照Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗HIV阳性
- 41093568ILD合并NSCLC不应被机械排除在ICI之外：日本全国数据提示ICI相关OS更长，但肺毒性和选择偏倚仍需前置讨论Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗合并ILD
- 41882889ICI肺炎风险评估应把既往IIP放到前台：403例不可切除晚期NSCLC队列显示IIP与肺炎独立相关Risk Factors for Pneumonitis in Patients with Unresectable Advanced Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）不可切除
- 41881050帕博利珠单抗按体重给药可作为成本敏感选项：单中心真实世界队列显示与固定剂量OS和安全性相近Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World Cohort.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）驱动阴性一线治疗
- 41922087NSAID暴露与ICI结局改善相关但不能直接指导加药：多中心双队列研究提示机制信号仍需前瞻验证Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗
- 41935145一线ICI重度irAE可提前分层：SEER-Medicare研究显示自身免疫病和化免联合风险更高Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗
- 41942994晚期NSCLC免疫治疗疗程仍缺统一答案：系统综述提示超过1年可能有利，超过2年未见清晰OS增益The optimal duration of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer: a systematic review of clinical trials.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）维持治疗长期治疗
- 41965971帕博利珠单抗治疗前需重视轻微间质异常：NSCLC回顾性队列显示基线ILA关联重度肺炎风险升高Pneumonitis risk from pembrolizumab in non-small cell lung cancer: Interstitial abnormalities matter, and so does treatment.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）合并ILA
- 42035031合并ILD的晚期NSCLC不应被简单排除于PD-1单药之外：5年回顾性数据未见OS劣势，但肺炎风险显著升高Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）后线治疗合并ILD
- 42046015基线AEC可能同时提示免疫治疗获益和肺炎风险：回顾性生物标志物研究支持将疗效预测与毒性预警并行解读The dual role of baseline absolute eosinophil count in non-small cell lung cancer immunotherapy: a biomarker for enhanced efficacy and elevated risk of immune checkpoint inhibitor-related pneumonitis.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）后线治疗复发
- 42071088既往免疫治疗后再挑战只能作为筛选后选项：法国LIST 24个月结果显示可行性有限，不能泛化为晚期NSCLC后线常规策略Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）后线治疗进展后
- 42077146KRAS突变未预测非鳞NSCLC一线化免联合OS优势：33中心真实世界研究提示PFS更短，治疗选择仍需回到PD-L1、共突变和后线可及性Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）KRAS突变一线治疗含骨转移亚组
- 42268349KRAS Q61突变NSCLC不能作为单一小类处理：Q61H和Q61L共突变谱不同，免疫治疗结局信号也需分型解读Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）KRAS突变一线治疗
- 42373128帕博利珠单抗Q3W转Q6W后肺炎风险可能与既往峰浓度波动有关：79例NSCLC药代队列提示固定换间隔前需看个体暴露稳定性Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗后线治疗
- 42448175PD-L1≥50%晚期NSCLC的AdvanTIG-302：PFS和ORR仅作描述性解读AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗
跨分期/范围未限定NSCLC × ADC
2项研究
- 42214392PD-L1阳性晚期NSCLC探索ADC联合免疫一线无化疗强化：OptiTROP-Lung05显著延长PFS，但对照选择限制治疗排序Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）驱动阴性PD-L1阳性一线治疗
- 42330841NSCLC早期ADC研究需报告性别安全性：Gustave Roussy队列显示女性高级别以下但临床相关毒性更多Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）后线治疗
跨分期/范围未限定NSCLC × 双抗
2项研究
- 42218899晚期鳞状NSCLC一线PD-1/VEGF双抗获得OS优势：HARMONi-6主动对照显示生存改善，但高级别毒性和出血更多Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）III期不可切除一线治疗
- 42285994PD-L1阴性晚期NSCLC仍在寻找强化免疫方案：卡度尼利单抗联合化疗II期达到12个月PFS门槛Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）PD-L1阳性一线治疗
跨分期/范围未限定NSCLC × 抗血管
3项研究
- 41825453PD-L1阳性驱动阴性晚期NSCLC一线免疫单药受到挑战：CAMPASS显示benmelstobart联合安罗替尼延长PFS，但3级以上毒性明显增加Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）驱动阴性PD-L1阳性一线治疗
- 42336655非鳞NSCLC肝转移可能需要抗VEGF参与免疫化疗：IMpower后验分析提示贝伐珠单抗可恢复获益，但仍需前瞻确认VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）驱动阴性一线治疗含肝转移亚组
- 42398850SMARCA4缺陷NSCLC免疫联合策略有真实世界信号：多中心队列显示免疫化疗加抗血管生成PFS较化疗更长，仍受回顾性设计限制Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）SMARCA4缺陷一线治疗后线治疗
跨分期/范围未限定NSCLC × 化疗
3项研究
- 41965561老年驱动阴性NSCLC可考虑降低化疗强度：大型回顾性研究显示低强度化免优于免疫单药，但不能消除选择偏倚Efficacy and safety of low-intensity chemotherapy combined with immunotherapy in elderly patients with locally advanced and metastatic non-small cell lung cancer: a retrospective analysis.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）驱动阴性一线治疗
- 42036883非鳞NSCLC维持期继续加培美曲塞未显示额外生存收益：多中心真实世界研究提示毒性增加，减药评估应进入维持治疗讨论Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs. immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study.驱动基因阴性/未知NSCLC› 跨分期/范围未限定III-IV期（跨范围）维持治疗
- 42240993PD-L1高表达晚期NSCLC免疫单药默认地位受到再检验：Meta分析提示免疫化疗OS和PFS更优，但仍缺少直接前瞻随机确认PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）驱动阴性PD-L1阳性一线治疗
跨分期/范围未限定NSCLC × 支持治疗
2项研究
- 41711151针灸或艾灸辅助标准治疗使NSCLC患者化疗相关恶心呕吐风险相对降低68%Effectiveness of Acupuncture and Moxibustion for Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Standard Treatment: A Systematic Review and Meta-Analysis.驱动基因阴性/未知NSCLC› 跨分期/范围未限定
- 42541899FLEX试验：短程口服亚叶酸减轻培美曲塞化疗早期粒缺Prophylactic folinic acid prevents pemetrexed myelosuppression: A randomized trial toward safer treatment with chemotherapy in non-small cell lung cancer.驱动基因阴性/未知NSCLC› 跨分期/范围未限定晚期（范围未限定）一线治疗后线治疗
局限期SCLC × 放疗
3项研究
- 41762408高龄低负荷LS-SCLC单纯放疗与放化疗生存相近：3649例SEER队列显示积极治疗中位OS为11个月，高于姑息照护的4个月，T1N0-2或T2N0患者单纯放疗与放化疗生存无显著差异Therapeutic strategies for elderly patients with unresectable limited-stage small cell lung cancer.SCLC› 局限期局限期不可切除
- 42050661LS-SCLC选择性照射高危淋巴结区值得重新讨论：PSM回顾性研究显示ENI较IFRT改善OS、PFS和远处失败，但仍需随机验证Elective nodal irradiation of high-risk regions is superior to involved field radiotherapy for limited-stage small cell lung cancer: a propensity score-matched retrospective study.SCLC› 局限期局限期
- 4208612561.2 Gy同步推量TRT在LS-SCLC中提供成熟长期随访：CALGB 30610/RTOG 0538显示可接受结局，但不能确立优于45 Gy BID或高剂量QDBrief Report: Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: CALGB 30610 (Alliance) / RTOG 0538.SCLC› 局限期局限期
局限期SCLC × 免疫
3项研究
- 41832629局限期SCLC免疫同步前移仍需随机验证：度伐利尤单抗并入同步放化疗显示可行，但单臂II期不能改写标准Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial.SCLC› 局限期局限期巩固治疗
- 41921748ADRIATIC亚组支持LS-SCLC度伐利尤单抗巩固的适用边界：不同cCRT方案和PCI状态下获益方向一致Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.SCLC› 局限期局限期巩固治疗
- 42225651局限期SCLC同步放化疗期间加入免疫治疗仍属探索：SINCE-01长期随访给出PFS信号，但22例单臂研究不能改写标准Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): a phase II clinical trial.SCLC› 局限期局限期局部晚期一线治疗同步放化疗
广泛期SCLC × 放疗
2项研究
- 41934389老年ES-SCLC不应自动放弃胸部巩固放疗：真实世界分析提示fit人群在一线免疫化疗后可能获益Real-world efficacy of first-line immunochemotherapy combined with thoracic radiotherapy in elderly patients with extensive-stage small cell lung cancer: a single-center retrospective study.SCLC› 广泛期广泛期一线治疗巩固治疗
- 42322244ES-SCLC不应机械接受PCI：Meta分析显示PCI降低脑转移风险，但生存获益主要局限于局限期SCLCProphylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta-Analysis.SCLC› 广泛期广泛期初始治疗后
广泛期SCLC × 免疫
6项研究
- 41761164斯鲁利单抗联合EP在ES-SCLC网络Meta分析中获得最大PFS降幅：34项RCT的间接比较显示其相对EP的OS HR为0.63、PFS HR为0.48Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer - a grade-assessed network meta-analysis of randomized controlled trials.SCLC› 广泛期广泛期一线治疗
- 41796863RATIONALE-312长期随访支持替雷利珠单抗一线化免延续OS获益：ES-SCLC随机III期延伸分析显示生存优势维持，但不构成免疫药物间排序证据First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.SCLC› 广泛期广泛期一线治疗维持治疗
- 41825179ES-SCLC一线化免后ICI再挑战可进入后线讨论：真实世界研究显示ORR、PFS2和OS改善，但获益人群仍需前瞻性界定Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study.SCLC› 广泛期广泛期一线治疗后线治疗进展后复发进展
- 41950998ES-SCLC一线TIGIT联合仍未封板：SKYSCRAPER-02C中国队列显示PFS数值改善，OS和人群筛选仍需更稳证据SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China.SCLC› 广泛期广泛期一线治疗
- 42240984ES-SCLC一线斯鲁利单抗长期随访支持持续生存获益：ASTRUM-005二次分析显示4年OS率提高，但仍是既有III期试验更新First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.SCLC› 广泛期广泛期一线治疗
- 42458439中国真实世界ES-SCLC中，斯鲁利单抗联合化疗OS分布与注册试验相近Real-world serplulimab plus chemotherapy for extensive-stage small cell lung cancer in china: an external validation of ASTRUM-005 trial.SCLC› 广泛期广泛期一线治疗含肝转移亚组
广泛期SCLC × 双抗
4项研究
- 41880872tarlatamab真实世界毒性需要前置分层：ES-SCLC九中心队列提示高病灶负荷、肝病变和CNS病灶影响CRS/ICANS风险Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice.SCLC› 广泛期广泛期后线治疗进展含脑转移亚组含肝转移亚组
- 42377743铂难治或耐药ES-SCLC二线治疗出现间接比较证据：tarlatamab较紫杉类或CAV延长OS，但MAIC不能替代头对头随机试验Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.SCLC› 广泛期广泛期转移性IV期后线治疗复发难治耐药
- 42418753塔拉妥单抗从住院监测走向门诊路径仍要严管CRS和ICANS：49例真实世界项目显示可行，但首两周期仍有20%需收入院Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.SCLC› 广泛期广泛期转移性IV期后线治疗复发
- 42497381经治ES-SCLC出现EGFR-HER3双特异性ADC活性Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.SCLC› 广泛期广泛期后线治疗
广泛期SCLC × 抗血管
2项研究
- 42185290ES-SCLC维持治疗加入安罗替尼出现PFS信号：DURABLE随机II期支持继续验证度伐利尤单抗联合抗血管生成策略Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.SCLC› 广泛期广泛期维持治疗
- 42486095经治ES-SCLC两种单臂新方案均待随机比较Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.SCLC› 广泛期广泛期后线治疗
广泛期SCLC × 化疗
2项研究
- 41791703lurbinectedin联合irinotecan为复发SCLC提供早期后线信号：phase I/II转化研究显示较高ORR，但仍处于单臂验证阶段Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.SCLC› 广泛期广泛期后线治疗复发进展
- 42567006一线免疫治疗并未增强广泛期小细胞肺癌二线化疗疗效：法国真实世界研究提示跨线免疫协同有限Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohortSCLC› 广泛期广泛期后线治疗进展后
SCLC（分期未限定） × 化疗
2项研究
- 41937137二线SCLC低成本增效信号值得验证：白蛋白紫杉醇联合辛伐他汀提高DCR、ORR和PFS但未改善OSEfficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial.SCLC› 跨分期/范围未限定后线治疗复发进展
- 41962051真实世界SCLC剂量调整不等于治疗失败：Karolinska队列显示完成治疗暴露和风险分层比名义剂量更关键Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach.SCLC› 跨分期/范围未限定一线治疗后线治疗低PS